Compare · LUCY vs STAA
LUCY vs STAA
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.16B, about 126.2x LUCY ($9.2M).
- LUCY has been more active in the news (12 items in the past 4 weeks vs 11 for STAA).
- STAA has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $9.2M
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 12
- 11
- Recent ratings
- 0
- 25
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest LUCY
- Chief Financial Officer Gayle Oswald was granted 32,466 shares and sold $13,491 worth of shares (15,533 units at $0.87), increasing direct ownership by 591% to 19,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad sold $11,874 worth of shares (13,627 units at $0.87) and was granted 41,800 shares, increasing direct ownership by 220% to 40,977 units (SEC Form 4)
- Chief Operating Officer Abondano Joaquin was granted 29,600 shares and sold $8,414 worth of shares (9,799 units at $0.86), increasing direct ownership by 380% to 25,012 units (SEC Form 4)
- Chief Executive Officer Gross Harrison R. was granted 49,200 shares and sold $24,411 worth of shares (27,738 units at $0.88), increasing direct ownership by 156% to 35,195 units (SEC Form 4)
- Chief Technology Officer Cohen David Eric was granted 36,400 shares and sold $14,587 worth of shares (15,769 units at $0.93), increasing direct ownership by 307% to 27,342 units (SEC Form 4)
- Innovative Eyewear, Inc. Announces Strategic Alliance with HTC Corporation
- Innovative Eyewear Announces Expansion Into More than 150 Stores of One of the Largest Big Box Retailers in the United States
- Innovative Eyewear, Inc. Announces Major New AI and News Features for Lucyd App
- SEC Form 10-Q filed by Innovative Eyewear Inc.
- Innovative Eyewear Inc. Reports Record Second Quarter 2026 Results
Latest STAA
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Second Quarter 2026 Results
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- President and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)
- STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer